Skip to main content

Table 5 Number of relapses in each study group during the 12-month study period

From: The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study

Number of relapses Groups
Study group
Number (%)
Control group
Number (%)
0 18 (90) 0 (0)
1 2 (10) 11 (36.6)
2 0 (0) 19 (63.3)